The genetics of drug efficacy: opportunities and challenges

被引:0
|
作者
Matthew R. Nelson
Toby Johnson
Liling Warren
Arlene R. Hughes
Stephanie L. Chissoe
Chun-Fang Xu
Dawn M. Waterworth
机构
[1] Target Sciences,
[2] GlaxoSmithKline,undefined
[3] King of Prussia,undefined
[4] Target Sciences,undefined
[5] GlaxoSmithKline,undefined
[6] GlaxoSmithKline,undefined
[7] PAREXEL International,undefined
[8] Target Sciences,undefined
[9] GlaxoSmithKline,undefined
[10] Present address: Acclarogen,undefined
[11] Cambridge CB4 0WS,undefined
[12] UK.,undefined
来源
Nature Reviews Genetics | 2016年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
To date, there have been at least 76 genome-wide association studies and a large number of candidate gene studies of drug efficacy. From these, there are at least 12 drugs with high-confidence genetic predictors of drug efficacy.Genetic predictors of drug efficacy are mostly common variants with a range of effect sizes; most have been discovered through studies of sensitive quantitative measures of drug response, and all but one were discovered following drug approval.Less than 20% of drugs are estimated to have common genetic predictors of efficacy that are large enough to inform clinical decision making.There are limited scenarios in which genetics can 'rescue' a trial that fails owing to lack of efficacy. However, advances in genetic technologies can allow for cost-effective screening for genetic predictors with potential clinical utility during the course of clinical development.Pharmaceutical and academic researchers should combine resources to study the efficacy pharmacogenetics of marketed drugs.
引用
收藏
页码:197 / 206
页数:9
相关论文
共 50 条
  • [11] Unraveling the Genetics of Congenital Hypothyroidism: Challenges and Opportunities
    Wassner, Ari J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : E3464 - E3465
  • [12] Sleep Duration, Genetics, and Atherosclerosis: Challenges and Opportunities
    Martins, Ana Vitoria Vitoreti
    Krul, Larissa T.
    Drager, Luciano F.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2024, 121 (09)
  • [13] Modifier genetics in neuropsychiatric disease: challenges and opportunities
    Elizabeth K Ruzzo
    Andrea L Pappas
    David B Goldstein
    Genome Biology, 13
  • [14] Autism genetics: opportunities and challenges for clinical translation
    Vorstman, Jacob A. S.
    Parr, Jeremy R.
    Moreno-De-Luca, Daniel
    Anney, Richard J. L.
    Nurnberger, John I., Jr.
    Hallmayer, Joachim F.
    NATURE REVIEWS GENETICS, 2017, 18 (06) : 362 - 376
  • [15] Modifier genetics in neuropsychiatric disease: challenges and opportunities
    Ruzzo, Elizabeth K.
    Pappas, Andrea L.
    Goldstein, David B.
    GENOME BIOLOGY, 2012, 13 (03)
  • [16] Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy
    Mehta, Geeta
    Hsiao, Amy Y.
    Ingram, Marylou
    Luker, Gary D.
    Takayama, Shuichi
    JOURNAL OF CONTROLLED RELEASE, 2012, 164 (02) : 192 - 204
  • [17] Drug-drug cocrystals: Opportunities and challenges
    Xiaojuan Wang
    Shuzhang Du
    Rui Zhang
    Xuedong Jia
    Ting Yang
    Xiaojian Zhang
    AsianJournalofPharmaceuticalSciences, 2021, 16 (03) : 307 - 317
  • [18] Drug-drug cocrystals: Opportunities and challenges
    Wang, Xiaojuan
    Du, Shuzhang
    Zhang, Rui
    Jia, Xuedong
    Yang, Ting
    Zhang, Xiaojian
    ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 16 (03) : 307 - 317
  • [19] Minding the gap in HIV host genetics: opportunities and challenges
    Gingras, Shanelle N.
    Tang, David
    Tuff, Jeffrey
    McLaren, Paul J.
    HUMAN GENETICS, 2020, 139 (6-7) : 865 - 875
  • [20] Challenges and opportunities for evidence-based genetics practice
    Tuckson, Reed V.
    GENETICS IN MEDICINE, 2009, 11 (01) : 1 - 2